The purpose of this study is to evaluate the quality of platelets collected on the Trima Accel system after storage for 5 days in a Platelet Additive Solution (PAS), called InterSol.

Platelets suspended in platelet additive solutions (PAS) have been collected and transfused in Europe for over 20 years. These PAS solutions outside of the United States (US) are not tied to an apheresis device; however in the US, PAS solutions have traditionally been linked to a corresponding apheresis device.

Currently in the US, there are two solutions approved by the Food and Drug Administration (FDA) as a PAS for the replacement of 65% plasma in platelet components. Isoplate Solution is approved for use with the Trima Accel® Automated Blood Collection System (Trima Accel System) and InterSol Solution is approved for use with the Amicus Separator System.

Terumo BCT is pursuing FDA clearance for InterSol in combination with the Trima Accel system in order to provide blood centers with the option to use InterSol as well as Isoplate Solution when collecting platelets to be stored in a PAS.

This is a prospective, open-label, multicenter, controlled study. Up to 40 healthy adult subjects will be enrolled in this study to ensure 24 evaluable subjects across two Investigational Sites. Evaluable is defined as the subject completing the recovery and survival procedure and neither the subject or the product meeting any of the Clinical Investigation Plan (CIP) analysis exclusion criteria.

The additional platelet donors account for screen failures, incomplete procedures and CIP exclusions.

Two (2) sets of platelets will be collected from each subject:

1. A Test unit - A hyperconcentrated platelet product collected on the Trima Accel system and diluted to a final ratio of 65% InterSol/35% plasma through the addition of InterSol directly to the platelet bag by the Trima Accel system after collection.
2. A Control sample - Fresh platelets prepared from a whole blood sample drawn from the same subject on Study Day 5 in accordance with standard procedure.

Eligible donors who have signed an informed consent will be enrolled.

SUBJECT PROCEDURES

Screening can be performed within 5 days of the apheresis procedure or combined with the Apheresis visit.

The following evaluations will be performed:

1. Informed consent will be obtained prior to initiating any study specific procedures
2. Eligibility will be confirmed
3. Demographics (age, gender, race, ethnic origin), height, and weight
4. Record medical history as per AABB criteria for healthy donors

Apheresis Visit

The following procedures will be performed:

1. Eligibility will be confirmed
2. Finger stick hemoglobin
3. Apheresis procedure

Apheresis procedures will be run according to the instructions and precautions described in the commercially available Trima Accel Operator's Manual.

The Investigator or designee will perform the venipuncture, monitor the subject during the collection, assess and provide any interventions for adverse effects, remove the needle, dress the puncture site and monitor subject through recovery.

The following information will be documented:

1. Trima procedure details
2. Adverse events (AEs)
3. Medications to treat adverse events
4. Device deficiencies

Infusion Day Visit

Five (5) days after a study subject has completed the apheresis procedure to collect Test platelets, they will return for the donation of fresh Control platelets, reinfusion of radiolabeled Test and Control platelets, and post-infusion sampling.

The following procedures will be conducted:

1. Confirm eligibility
2. Conduct pregnancy test for women of childbearing potential (serum or urine)
3. Review adverse events since the previous visit
4. Collect a whole blood sample for the production of Control platelets
5. Radiolabel Test and Control platelets and prepare for infusion
6. Infuse radiolabeled combined Test and Control platelets into subject's vein
7. Collect a 5-10 mL blood sample for pre- and post-infusion testing using the opposite arm as for the infusion

The following will be documented:

1. Vital signs (blood pressure, heart rate, temperature)
2. Adverse events
3. Medications to treat adverse events

The subject will return to the study site daily (except on weekends) between Study Day 6 and Study Day 12 . A total of 5 blood samples are required to be collected in this 7 day period in order for the subject's data to be evaluable. The subject will also return to the study site for a final visit on Study Day 16.

At each of these visits a blood sample will be collected for testing.

The following will be documented:

1. Adverse events
2. Medications to treat adverse events

Inclusion Criteria:

1. Age 18 years or older
2. Normal health status as per AABB criteria for a healthy donor
3. Able to commit to the study schedule
4. Meets the inclusion criteria defined by the Blood Center for an apheresis platelet with PAS collection on the Trima Accel system. These criteria are based on FDA Regulations and AABB standards. Note: Participants who are deferred from volunteer community donations because of travel restrictions, piercings, or tattoos may participate in the study, as products are not transfused
5. Participants of child-bearing potential (either male or female) must agree to use an effective method of contraception during the course of the study
6. Female of childbearing potential must be willing to take a pregnancy test prior to infusion of radiolabeled platelets
7. Has given written informed consent

Exclusion Criteria:

1. Previously received radiation therapy
2. Has been diagnosed with a platelet disorder (ie, platelet dysfunction)
3. Already participated in 4 research studies involving radioisotopes within the contemporaneous calendar-year
4. Pregnant or nursing females
5. Participation currently, or within the last 12 months, in another investigational trial that would potentially interfere with the analysis of this investigation
6. History of known hypersensitivity to indium or chromium
7. Treatment with aspirin or aspirin containing medications within 7 days of apheresis or treatment with non-steroidal anti inflammatory drugs (NSAID), anti-platelet agents or other drugs affecting platelet viability within 3 days of apheresis (eg, ibuprofen or other NSAIDs)

Safety Analysis Set = Includes all participants who underwent any study related apheresis procedure, defined as having had venipuncture for apheresis.

Adverse events that occurred on or after the start of the apheresis procedure (time of venipuncture) until study completion (16 days +/- 1 day).

Treatment emergent adverse events were analyzed in the Safety Analysis set. Treatment began with the apheresis venipuncture.